drugset / Trial / NCT04927481
A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, single-arm, phase II study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in patients with advanced HER2 negative breast cancer.
Timeline
- Start
- 2021-06-11
- Primary completion
- 2023-01-17
- Completion
- 2023-01-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mitoxantrone | Small molecule | 20 mg/m2 | Intravenous |